ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,220.90
0.24%
S&P ASX All Technology
3,825.10
-0.11%
Brent Oil
73.285
0.00%
US Dollar vs AUD
1.60155
-0.07%
Bitcoin
97,989.03
-0.69%
Pepperstone
Advertisement
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Rigel Pharmaceuticals Inc (RIGL) Share Price

Rigel Pharmaceuticals Inc

Rigel Pharmaceuticals Inc (RIGL)

NASDAQ
16.44
-0.71
(-4.14%)
Closed 25 December 8:00AM
Delayed by 15 minutes
16.44
0.00
(0.00%)
After Hours: 8:59AM
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
16.44
Bid
15.91
Offer
16.42
Volume
490,880
14.63 Day's Range 16.82
7.4843 52 Week Range 29.82
Market Cap
289.591M
Previous Close
17.15
Open
16.82
Last Trade
1
@
15.91
Last Trade Time
Financial Volume
US$ 7,846,615
VWAP
15.9848
Average Volume (3m)
201,782
Shares Outstanding
17,615,040
Dividend Yield
-
PE Ratio
-11.54
Earnings Per Share (EPS)
-1.42
Revenue
116.88M
Net Profit
-25.09M

About Rigel Pharmaceuticals Inc

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For mor... Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit https://www.rigel.com/. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.rigel.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Rigel Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker RIGL. The last closing price for Rigel Pharmaceuticals was US$17.15. Over the last year, Rigel Pharmaceuticals shares have traded in a share price range of US$ 7.4843 to US$ 29.82.

Rigel Pharmaceuticals currently has 17,615,040 shares in issue. The market capitalisation of Rigel Pharmaceuticals is US$302.10 million. Rigel Pharmaceuticals has a price to earnings ratio (PE ratio) of -11.54.

Ask ADVFN Intelligence (AI)

RIGL Latest News

More News

Form 8-K - Current report

10 December 2024
Edgar (US Regulatory)

Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition

Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition PR Newswire SOUTH SAN FRANCISCO, Calif., Dec. 9, 2024 R289 was...

10 December 2024
PR Newswire (US)

Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS

Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS PR Newswire SOUTH SAN FRANCISCO, Calif., Dec. 2, 2024 SOUTH SAN FRANCISCO, Calif., Dec. 2, 2024 /PRNewswire/...

03 December 2024
PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities

27 November 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

27 November 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

27 November 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

15 November 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

15 November 2024
Edgar (US Regulatory)

Rigel to Present at the Jefferies London Healthcare Conference

Rigel to Present at the Jefferies London Healthcare Conference PR Newswire SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 /PRNewswire/ -- Rigel...

13 November 2024
PR Newswire (US)

Form 8-K - Current report

08 November 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-3.26-16.548223350319.719.716.3818307217.30929169CS
4-9.4945-36.609535560725.934529.516.3819549621.80302153CS
120.160.98280098280116.2829.8213.570520178221.2646837CS
266.93873.01620711439.50229.827.484331147313.15826474CS
522.2415.774647887314.229.827.484379344412.37200717CS
156-11.86-41.908127208528.335.156.4216981113.78757117CS
260-5.16-23.888888888921.6556.4246239522.85596355CS

RIGL - Frequently Asked Questions (FAQ)

What is the current Rigel Pharmaceuticals share price?
The current share price of Rigel Pharmaceuticals is US$ 16.44
How many Rigel Pharmaceuticals shares are in issue?
Rigel Pharmaceuticals has 17,615,040 shares in issue
What is the market cap of Rigel Pharmaceuticals?
The market capitalisation of Rigel Pharmaceuticals is USD 302.1M
What is the 1 year trading range for Rigel Pharmaceuticals share price?
Rigel Pharmaceuticals has traded in the range of US$ 7.4843 to US$ 29.82 during the past year
What is the PE ratio of Rigel Pharmaceuticals?
The price to earnings ratio of Rigel Pharmaceuticals is -11.54
What is the cash to sales ratio of Rigel Pharmaceuticals?
The cash to sales ratio of Rigel Pharmaceuticals is 2.48
What is the reporting currency for Rigel Pharmaceuticals?
Rigel Pharmaceuticals reports financial results in USD
What is the latest annual turnover for Rigel Pharmaceuticals?
The latest annual turnover of Rigel Pharmaceuticals is USD 116.88M
What is the latest annual profit for Rigel Pharmaceuticals?
The latest annual profit of Rigel Pharmaceuticals is USD -25.09M
What is the registered address of Rigel Pharmaceuticals?
The registered address for Rigel Pharmaceuticals is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Rigel Pharmaceuticals website address?
The website address for Rigel Pharmaceuticals is www.rigel.com
Which industry sector does Rigel Pharmaceuticals operate in?
Rigel Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BAOSBaosheng Media Group Holdings Ltd
US$ 7.10
(310.40%)
58.74M
HOURHour Loop Inc
US$ 4.40
(207.69%)
97.42M
GTIGraphjet Technology
US$ 0.61
(168.72%)
265.48M
CREVCarbon Revolution Public Ltd
US$ 9.16
(135.48%)
26.95M
AVGRAvinger Inc
US$ 1.45
(125.72%)
107.53M
SLGLSol Gel Technologies Ltd
US$ 0.9798
(-40.62%)
3.07M
DRCTDirect Digital Holdings Inc
US$ 3.71
(-32.55%)
23.82M
CHEKCheck Cap Ltd
US$ 1.55
(-31.11%)
3.49M
SYTASiyata Mobile Inc
US$ 0.5178
(-30.83%)
2.63M
BTFValkyrie ETF Trust II CoinShares Bitcoin and Ether Stratagy ETF
US$ 15.47
(-30.38%)
147.98k
SVMHSRIVARU Holding Ltd
US$ 0.0338
(20.71%)
280.27M
GTIGraphjet Technology
US$ 0.61
(168.72%)
265.48M
LITMSnow Lake Resources Ltd
US$ 0.5849
(52.84%)
181.22M
LCIDLucid Group Inc
US$ 3.20
(3.23%)
108.75M
RGTIRigetti Computing Inc
US$ 11.35
(3.56%)
108.38M

RIGL Discussion

View Posts
dcaf7 dcaf7 8 months ago
Titles of olutasidenib presentations at ASCO:
1. Safety and efficacy of olutasidenib treatment in elderly patients with relapsed/refractory mIDH1 acute myeloid leukemia.
2. Patients with relapsed/refractory mIDH1 AML who proceeded to transplant after olutasidenib treatment.
3. Olutasidenib for mutated IDH1 acute myeloid leukemia: Final five-year results from the phase 2 pivotal cohort.
👍️0
Monksdream Monksdream 8 months ago
RIGL under $2
👍️0
Monksdream Monksdream 9 months ago
RIGL under $2
👍️0
dcaf7 dcaf7 9 months ago
Just published, "Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML)". The results of this phase 2 study support data from registrational cohort demonstrating that Olutasidenib works well in patients previously treated with venetoclax.
https://pubmed.ncbi.nlm.nih.gov/38538632/
👍️0
dcaf7 dcaf7 9 months ago
Good read on Olutasidenib
https://journals.lww.com/oncology-times/fulltext/2024/03000/olutasidenib_as_a_breakthrough_for_r_r_midh1_aml.25.aspx
Important further research: 1) studying whether olutasidenib can eliminate the stem cell fraction within each patient's IDH1-mutant AML; 2) characterization of synthetic lethality involving olutasidenib in IDH1-mutant AML.
👍️0
dcaf7 dcaf7 10 months ago
Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®
FEBRUARY 22, 2024 7:50AM EST
GAVRETO® (pralsetinib) is an FDA approved targeted therapy for the treatment of RET fusion-positive metastatic non-small cell lung cancer and advanced or metastatic thyroid cancer
Acquisition of established U.S. marketed product further expands Rigel's portfolio and leverages Rigel's existing infrastructure in both the institutional and community settings
GAVRETO generated ~$28M in U.S. net product sales in 2023
👍️0
bme bme 1 year ago
Rigl should be VTGN (Today) one day.
👍️0
bme bme 1 year ago
Yeah. Should be good Q.
👍️0
TucsonPhil TucsonPhil 1 year ago
Hopefully, the inducement grants are being used to hire qualified talent, rather than pad the wallets of friends and relatives.
👍️0
bme bme 1 year ago
Better be good.
👍️0
bme bme 1 year ago
Ugly.
👍️0
The Night Stalker The Night Stalker 2 years ago
nice
👍️0
The Night Stalker The Night Stalker 2 years ago
nice
👍️0
The Night Stalker The Night Stalker 2 years ago
base
👍️0
bme bme 2 years ago
What a shoot! Amazing.
👍️0
bme bme 2 years ago
The next quarter fin should include the rev for TAVALISSE. "In April, Rigel's partner Kissei announced the launch of TAVALISSE in Japan for the treatment of chronic ITP."
1. What else should we expect as for the rev?
2. Result of phase 3 of Fostamatinib3 COVID 19?
3. Status of Fostamatinib-ACTIV4 COVID 19?
4. Partnered Programs?
👍️0
The Night Stalker The Night Stalker 2 years ago
nice fins
👍️0
The Night Stalker The Night Stalker 2 years ago
gem
👍️0
The Night Stalker The Night Stalker 2 years ago
gem
👍️0
The Night Stalker The Night Stalker 2 years ago
easy
👍️0
bme bme 2 years ago
Nice spike AH today.
👍️0
bme bme 2 years ago
Higher low higher low.... next leg is North.
👍️0
The Night Stalker The Night Stalker 2 years ago
https://www.barchart.com/stocks/quotes/RIGL/technical-chart?plot=BAR&volume=total&data=I:120&density=H120&pricesOn=1&asPctChange=0&logscale=0&im=120&indicators=EXPMA(9);SMA(20);BBANDS(20,2);MACD(12,26,9)&sym=RIGL&grid=1&height=500&studyheight=100
👍️0
The Night Stalker The Night Stalker 2 years ago
https://www.barchart.com/stocks/quotes/RIGL/technical-chart?plot=BAR&volume=total&data=I:120&density=H120&pricesOn=1&asPctChange=0&logscale=0&im=120&indicators=EXPMA(9);SMA(20);BBANDS(20,2);MACD(12,26,9)&sym=RIGL&grid=1&height=500&studyheight=100
👍️0
bme bme 2 years ago
acting wild atm, but still healthy.
👍️0
The Night Stalker The Night Stalker 2 years ago
nice
👍️0
bme bme 2 years ago
Nice & Healthy.
👍️0
The Night Stalker The Night Stalker 2 years ago
quite the dip
👍️0
The Night Stalker The Night Stalker 2 years ago
ready
👍️0
The Night Stalker The Night Stalker 2 years ago
ready
👍️0
The Night Stalker The Night Stalker 2 years ago
red to green
👍️0
The Night Stalker The Night Stalker 2 years ago
red to green
👍️0
bme bme 2 years ago
Wonderful!
👍️0
The Night Stalker The Night Stalker 2 years ago
beauty
👍️0
The Night Stalker The Night Stalker 2 years ago
nice
👍️0
bme bme 2 years ago
Expect Q4 filing this week?
👍️0
bme bme 2 years ago
Be seeing that. Lot of 1.95 transactions so far
👍️0
TucsonPhil TucsonPhil 2 years ago
Revenue potential appears good. SP is slowly rising, and looks like it has been in accumulation for the past few weeks.
👍️0
bme bme 2 years ago
SP should be a lot higher since the Q4 revenue is more than double from last year...
👍️0
Welldoctor Welldoctor 2 years ago
Apparently insider buying reported on ST. Take it for what it’s worth.
👍️0
Welldoctor Welldoctor 2 years ago
RIGL news out
👍️0
bme bme 2 years ago
Looks like it will poke thru & bye bye 1 today.
👍️0
doesitreallymatter doesitreallymatter 2 years ago
Just like ABQQ. Right?
👍️0
subslover subslover 2 years ago
You are 1/2 way there!!!!
👍️0
KngmAz KngmAz 2 years ago
Wow - BOOM - we just went over a dollar - next step $10.00 - DON'T MISS OUT!!
👍️0
KngmAz KngmAz 2 years ago
This is a $10.00 per share stock in the very near future - EASILY!!
👍️0
Alaska40 Alaska40 2 years ago
I just bought in. Seems like a good run could come in the near future.
👍️0
subslover subslover 2 years ago
Consolidating nicely on Continuation from last week!
👍️0
bcapps66 bcapps66 2 years ago
LOL!
👍️0
THEMASTERS_SON THEMASTERS_SON 2 years ago
GIVE ME MY $2DOLLAS…YA BUM
👍️0

Your Recent History

NASDAQ
RIGL
Rigel Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads